FGFR2 (V564L)

FGFR2 · Variant type: point · HGVS: p.V564L

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Futibatinib	98.0%	2.0%	98.48
2	Pralsetinib	97.4%	2.6%	93.43
3	Selpercatinib	96.8%	3.2%	96.72
4	Sunitinib	96.2%	3.8%	91.73
5	Entrectinib	95.4%	4.6%	93.69
6	Defactinib	95.1%	4.9%	92.68
7	Repotrectinib	93.8%	6.2%	84.21
8	Fedratinib	93.0%	7.0%	96.21
9	Erdafitinib	86.5%	13.5%	95.71
10	Pacritinib	74.0%	26.0%	88.64
11	Alpelisib	70.2%	29.9%	97.22
12	Pemigatinib	69.2%	30.8%	98.23
13	Avapritinib	68.2%	31.8%	97.73
14	Gilteritinib	66.2%	33.8%	88.97
15	Pexidartinib	65.9%	34.1%	99.49
16	Upadacitinib	65.4%	34.6%	97.98
17	Tivozanib	63.0%	37.0%	92.42
18	Tenalisib	49.2%	50.8%	97.98
19	Rabusertib	34.9%	65.1%	98.74
20	Deucravacitinib	34.0%	66.0%	98.99
21	Darovasertib	33.7%	66.3%	96.99
22	Neratinib	27.9%	72.1%	93.18
23	Infigratinib	24.0%	76.0%	98.24
24	Palbociclib	17.4%	82.6%	98.75
25	Ripretinib	16.2%	83.8%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Futibatinib	98.0%	99.3%	-1.3%
Pralsetinib	97.4%	93.2%	+4.2%
Selpercatinib	96.8%	95.0%	+1.8%
Sunitinib	96.2%	—	—
Entrectinib	95.4%	81.5%	+13.9%
Defactinib	95.1%	—	—
Repotrectinib	93.8%	79.8%	+14.0%
Fedratinib	93.0%	—	—
Erdafitinib	86.5%	99.0%	-12.5%
Pacritinib	74.0%	—	—
Alpelisib	70.2%	98.9%	-28.8%
Pemigatinib	69.2%	98.7%	-29.5%
Avapritinib	68.2%	—	—
Gilteritinib	66.2%	—	—
Pexidartinib	65.9%	—	—
Upadacitinib	65.4%	—	—
Tivozanib	63.0%	—	—
Tenalisib	49.2%	96.0%	-46.8%
Rabusertib	34.9%	—	—
Deucravacitinib	34.0%	92.5%	-58.5%
Darovasertib	33.7%	—	—
Neratinib	27.9%	—	—
Infigratinib	24.0%	98.8%	-74.8%
Palbociclib	17.4%	—	—
Ripretinib	16.2%	85.4%	-69.1%

Cancer	Organ	Source
endometrial_carcinoma	Uterus	ref
carcinoma_liver	Liver	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.9ms